Advertisement
U.S. markets closed

Rezolute, Inc. (RZLT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
4.9900+0.2000 (+4.18%)
At close: 04:00PM EST
4.8500 -0.14 (-2.81%)
After hours: 05:13PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close4.7900
Open4.8100
Bid4.9500 x 100
Ask5.0400 x 100
Day's Range4.7000 - 5.0500
52 Week Range0.7200 - 6.1860
Volume399,292
Avg. Volume403,598
Market Cap289.136M
Beta (5Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-1.2700
Earnings DateFeb 11, 2025 - Feb 17, 2025
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
  • Simply Wall St.

    We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

    We can readily understand why investors are attracted to unprofitable companies. For example, Rezolute ( NASDAQ:RZLT...

  • GlobeNewswire

    Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

    Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), advancing in two late-stage, registrational clinical trials in two indications Phase 3 sunRIZE study on track; U.S. enrollment expected to commence in the first part of 2025 Phase 3 tumor HI study expected to commence in the first half of 2025 REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedic